Clinical trial · Observational
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Identification of de Novo Fanconi Anemia Patients Using FANCD2 Western Blots
NCT01146210CI-TRIAL-00022200completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to Fanconi anemia in patients with acute myeloid leukemia.
Conditions
Conditions (18)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Acute Erythroleukemia (M6) | Acute Erythroid Leukemia | ALIAS | 0.85 |
| Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Megakaryoblastic Leukemia | ALIAS | 0.90 |
| Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) | Childhood Acute Myeloid Leukemia with Minimal Differentiation | ALIAS | 0.90 |
| Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monoblastic Leukemia | ONTOLOGY_EXACT | 0.85 |
| Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Monocytic Leukemia | ONTOLOGY_EXACT | 0.85 |
| Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloid Leukemia with Maturation | ALIAS | 0.90 |
| Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myeloid Leukemia without Maturation | ALIAS |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-correlative
- description
- Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (2)
- measure
- Identification of children at high risk of having Fanconi anemia
- timeFrame
- Up to 5 months
- measure
- Identification of Fanconi anemia patients
- timeFrame
- Up to 5 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Treated on COG-2961 or COG-AAML03P1 * At high risk of having Fanconi anemia, defined as meeting one the following groups of clinical criteria: * Group 1: Prolonged neutropenia after induction, severe regimen-related toxicity (mucositis, veno-occlusive disease, end-organ damage) * Group 2: Early non-relapse death (induction, consolidation) * Group 3: Small-for-weight, secondary malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.